Objective: To investigate the expressions of histone lysine-specific demethylase 1 (LSD1), O⁶-methylguanine DNA methyltransferase (MGMT) and cell proliferation-associated antigen Ki-67 in high-grade glioma and their influences on prognosis. Methods: Sixty-five cases of grade Ⅲ and Ⅳ glioma confirmed by pathology from January 2011 to June 2017 in the First Affiliated Hospital of Xinjiang Medical University were selected. Immunohistochemistry (SP method) was used to detect the expressions of LSD1, MGMT and Ki-67 in pathological specimens. The therapeutic effect was evaluated by long-term follow-up. The relationships between the three markers and pathological grade, progression-free survival (PFS) and overall survival (OS) were analyzed. Results: The overall positive rates of LSD1, MGMT and Ki-67 in the 65 high-grade glioma specimens were 70.8% (46/65), 60.0% (39/65) and 100.0% (65/65), respectively. There were no significant differences in the expressions of LSD1 and MGMT in grade Ⅲ and Ⅳ glioma (χ²=1.588, P=0.208, χ²=0.013, P=0.908). Ki-67 expression (+ ), (+ + ), (+ + + ) in grade Ⅳ glioma were observed in 18, 19 and 11 cases, respectively. Ki-67 expression (+ ), (+ + ) in grade Ⅲ glioma were observed in 11, 5 cases, and 1 case was (+ + + ), and the difference in expression intensity between the two groups was statistically significant (Z=-2.083, P=0.037). Log-rank test showed that the positive expressions of LSD1, MGMT and Ki-67 were negatively correlated with the PFS of patients with high-grade glioma (χ²=12.217, P=0.007; χ²=4.446, P=0.035; χ²=12.536, P=0.002), also were negatively correlated with OS (χ²=11.708, P=0.008; χ²=6.637, P=0.010; χ²=11.807, P=0.003). Grade Ⅳ patients were more likely to have relapse progression than grade Ⅲ patients (χ²=6.573, P=0.010), and OS was shorter (χ²=3.974, P=0.046). Cox proportional hazards model analysis showed that the expressions of LSD1 (HR=1.361, 95%CI: 1.094-1.694, P=0.006; HR=1.406, 95%CI: 1.117-1.771, P=0.004) and Ki-67 (HR=1.703, 95%CI: 1.175-2.468, P=0.005; HR=1.778, 95%CI: 1.209-2.616, P=0.003) were the independent prognostic risk factors for PFS and OS of patients with high-grade glioma. Correlation analysis results showed that the expression of MGMT was positively correlated with the expression of LSD1 (r=0.406, P=0.001). Conclusion LSD1, MGMT and Ki-67 have higher positive expression rates in high-grade glioma. MGMT is a prognostic factor for high-grade glioma, and LSD1 and Ki-67 can be used as independent predictors of prognosis for high-grade gliomas.

Objective To explore the protective effect of DWK skin protectant and Sanyrene for prevention of acute radiation skin injury in radiation field among liver cancer patients with Cyberknife therapy. Methods A total of 100 liver cancer patients with Cyberknife therapy were selected by convenience sampling from March to November 2016. They were randomly divided into the group of DWK and the group of Sanyrene with 50 cases in each group. Skins in radiation field on hepatic region of patients in two groups used DWK skin protectant and Sanyrene respectively since one day before radiotherapy. The acute radiation skin injury of radiation field on hepatic region was observed from one day before treatment to two weeks the end of treatment during Cyberknife therapy.Results The scores of The Radiation Induced Skin Reaction Assessment Scale (RISRAS), an instrument for assessing the degree of acute radiation skin injury of radiation field on hepatic region, of patients in two groups increased with the increasing cumulated dose of irradiation with significant differences (F=3.780, 12.325;P<0.05). There were statistically significant differences in evaluations at the fifth and beyond between two groups (t=5.213, 12.437, 16.846;P<0.05).Conclusions Intervention for local prevention can alleviate the acute radiation skin injury in radiation field on hepatic region among liver cancer patients with Cyberknife therapy. The protective effect of DWK skin protectant on skin in radiation field on hepatic region among liver cancer patients with Cyberknife therapy is better than that of Sanyrene.

We present GranatumX, a next-generation software environment for single-cell RNA sequencing (scRNA-seq) data analysis. GranatumX is inspired by the interactive webtool Granatum. GranatumX enables biologists to access the latest scRNA-seq bioinformatics methods in a web-based graphical environment. It also offers software developers the opportunity to rapidly promote their own tools with others in customizable pipelines. The architecture of GranatumX allows for easy inclusion of plugin modules, named Gboxes, which wrap around bioinformatics tools written in various programming languages and on various platforms. GranatumX can be run on the cloud or private servers and generate reproducible results. It is a community-engaging, flexible, and evolving software ecosystem for scRNA-seq analysis, connecting developers with bench scientists. GranatumX is freely accessible at http://garmiregroup.org/granatumx/app.